1-3 of 3
Amin Azmon
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Effect of Deferasirox Combined with Erythropoietin Versus Erythropoietin Alone on Erythroid Response in Patients with Low- and Int-1-Risk Myelodysplastic Syndromes: Results of the Phase II Kallisto Trial

Norbert Gattermann, MD, Rosa Coll, MD, Lutz Jacobasch, Allameddine Allameddine, Laurie DeBonnett, Amin Azmon, Jie Jin
Journal: Blood
Blood (2017) 130 (Supplement 1): 2984.
https://doi.org/10.1182/blood.V130.Suppl_1.2984.2984
Published: 2017
Journal Articles

Impact of Age and Type of Underlying Disease on Long-Term Safety and Efficacy in Patients with Transfusional Hemosiderosis Treated with Deferasirox: Results from a 3-Year Non-Interventional Study (SENTINEL)

Mohsen Elalfy, Baba Inusa, David Beneitez, Blanca Xicoy, MD, Maria Soledad Duran Nieto, Andreas Bruederle, Amin Azmon, Amal El-Beshlawy
Journal: Blood
Blood (2016) 128 (22): 4831.
https://doi.org/10.1182/blood.V128.22.4831.4831
Published: 2016
Journal Articles

Treatment Outcomes in Patients with Transfusional Hemosiderosis Who Received Deferasirox for up to 3 Years: Results from Sentinel Study

Mohsen Elalfy, Baba Inusa, David Beneitez, Blanca Xicoy, MD, Maria Soledad Duran Nieto, Andreas Bruederle, Amin Azmon, Amal El-Beshlawy
Journal: Blood
Blood (2016) 128 (22): 4834.
https://doi.org/10.1182/blood.V128.22.4834.4834
Published: 2016